Ikonisys Announces the Completion of New Financing via the Issuance of a €0.5m Private Note
03 August 2023 - 6:37PM
Business Wire
Regulatory News:
Ikonisys SA (ISIN Code: FR00140048X2 / Mnemonic: ALIKO),
a company specializing in the early and accurate detection of
cancer with a unique fully-automated solution for medical
diagnostic labs, announces today the agreement for a new financing
via the issuance of a €0.5m non-convertible Note subscribed by LPE
II LP, a Limited Partnership registered in Scotland and managed by
Columbia Threadneedle Investments. The net proceeds of €0.5m will
be used to support the Company’s financial flexibility in the
context of the successful deployment of the commercial
strategy.
The Note is issued at a price equal to 100% of its par value,
amounting to €0.5m and accrues interest at an annual rate of 10%.
The duration of the Note is 18 months from its date of issuance
(the Maturity Date). The Company will have at any time the
possibility to redeem the Note. Repayment of principal and interest
(unless redeemed earlier by the Company) of the Note will be made
on the Maturity Date in cash.
Alessandro Mauri, Chief Financial Officer of Ikonisys,
stated: “We are pleased to announce this deal, that will give the
company the financial flexibility to continue pushing our
short-term commercial strategy. We are honored that an important
financial investor such as Columbia Threadneedle Investments,
believes in our project and decided to support our mission, which
is to continue to push the boundaries of cancer diagnostics,
providing laboratories with cutting-edge technologies for the
earlier detection of cancer cells”.
About Ikonisys Ikonisys SA is a cell-based diagnostics
company based in Paris (France), New Haven (Connecticut, USA) and
Milan (Italy) specialized in the early and accurate detection of
cancer. The company develops, produces and markets the proprietary
Ikoniscope20® platform, a fully-automated solution designed to
deliver accurate and reliable detection and analysis of rare and
very rare cells. Ikonisys has received FDA clearance for several
automated diagnostic applications, which are also marketed in
Europe under CE certification. Through its breakthrough
fluorescence microscopy platform, the company continues to develop
a stream of new tests, including liquid biopsy tests based on
Circulating Tumor Cells (CTC).
For further information, please go to www.Ikonisys.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230803291893/en/
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Aurélie Manavarere/Louis-Victor Delouvrier
INVESTOR Relations Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94
92
NewCap Nicolas Merigeau Media Relations
Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Ikonisys (EU:ALIKO)
Historical Stock Chart
Von Mai 2023 bis Mai 2024